Forester Medical

Working Days : Mondays through Friday
Contact : /

Product Detail

Biocan novel DHPPI, Lyophilisate and solvent for suspension for injection for dogs

 

Canine live vaccine against parvovirosis, distemper, inf. hepatitis, inf. laryngotracheitis and parainfluenza.

Composition per 1 ml dose:

Lyophilisate (live attenuated):

Canine Distemper virus, strain CDV Bio 11/A - min. 103.1 TCID50*, max. 105.1 TCID50*
Canine Adenovirus Type 2, strain CAV-2 Bio 13 - min. 103.6 TCID50*, max. 105.3 TCID50*
Canine Parvovirus Type 2b, strain CPV-2b Bio 12/B - min. 104.3 TCID50* , max. 106.6 TCID50*
Canine Parainfluenza Type 2 virus, strain CPiV-2 Bio 15 - 103.1 TCID50*, max. 105.1 TCID50*

* Tissue culture infectious dose – 50%

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection.

Lyophilisate: Spongy matter, white colour. Solvent: Clear colourless liquid.

Target species:

Dogs

Indications for use, specifying the target species:

Active immunization of dogs from 6 weeks of age.

  • to prevent mortality and clinical signs caused by canine distemper virus
  • to prevent mortality and clinical signs caused by canine adenovirus type 1
  • to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2
  • to prevent clinical signs, leukopenia and viral excretion caused by canine
  • to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus

Onset of immunity:

- 3 weeks after the first vaccination for CDV, CAV, CPV,

- 3 weeks after completion of the primary course for CPiV

Duration of immunity:

At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2 and canine parvovirus. At least one year following the primary vaccination course for canine parainfluenza virus.
The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.

 

Bioveta